Sarecycline, sold under the brand name Seysara, is a narrow-spectrumtetracycline-derived antibiotic medication.[2][3] It is specifically designed for the treatment of acne, and was approved by the FDA in October 2018 for the treatment of inflammatory lesions of non-nodular moderate to severe acne vulgaris in patients 9 years of age and older.[1] Two randomized and well-controlled clinical trials reported efficacy data on both facial and truncal acne (back and chest).[4] Efficacy was assessed in a total of 2002 subjects 9 years of age and older.[1] Unlike other tetracycline-class antibiotics, sarecycline has a long C7 moiety that extends into and directly interact with the bacterial messenger RNA (mRNA).[5] The spectrum of activity is limited to clinically relevant Gram-positive bacteria, mainly Cutibacterium acnes, with little or no activity against Gram-negative bacterialmicroflora commonly found in the human gastrointestinal tract.[6]
Medical uses
Sarecycline, is indicated for the treatment of inflammatory lesions of non-nodular moderate to severe acne vulgaris.[1]
^"Sarecycline". PubChem. U.S. National Library of Medicine. Retrieved 5 September 2020.
^Moore A, Green LJ, Bruce S, Sadick N, Tschen E, Werschler P, et al. (September 2018). "Once-Daily Oral Sarecycline 1.5 mg/kg/day Is Effective for Moderate to Severe Acne Vulgaris: Results from Two Identically Designed, Phase 3, Randomized, Double-Blind Clinical Trials". Journal of Drugs in Dermatology. 17 (9): 987–996. PMID30235387.
